Photon-counting CT-derived hepatic extracellular volume quantification for noninvasive risk stratification of clinically significant portal hypertension (CSPH): a prospective cohort study - Takeaways - MDSpire

Photon-counting CT-derived hepatic extracellular volume quantification for noninvasive risk stratification of clinically significant portal hypertension (CSPH): a prospective cohort study

  • By

  • Tatjana Dell

  • Verena Tischler

  • Dario Zocholl

  • Narine Mesropyan

  • Alice Margarida Jacob

  • Johannes Chang

  • Bernhard Schmidt

  • Claus Christian Pieper

  • Alexander Isaak

  • Patrick Kupczyk

  • Carsten Meyer

  • Julian Luetkens

  • Christian Strassburg

  • Christian Jansen

  • Daniel Kuetting

  • December 23, 2025

  • 0 min

Share

  • 1

    Chronic liver disease and cirrhosis are major global health issues, with significant mortality linked to HCV, HBV, and increasing metabolic liver diseases.

  • 2

    Clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) greatly increases the risk of severe complications.

  • 3

    Current CSPH diagnosis relies on invasive hepatic venous pressure gradient measurement, prompting the need for noninvasive assessment methods.

  • 4

    Photon-counting CT (PCCT) offers a promising approach for quantifying hepatic extracellular volume (ECV), potentially improving CSPH risk stratification.

  • 5

    This study evaluates the effectiveness of PCCT-derived ECV in stratifying CSPH risk alongside established noninvasive liver disease assessment techniques.

Original Source(s)

Related Content